ClinicalTrials.gg
CompletedNCT00867113Updated Mar 14, 2018Results posted

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

A Phase 2 interventional study of imatinib mesylate in Gastrointestinal Stromal Tumor (GIST), sponsored by Novartis Pharmaceuticals. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.

Enrollment
17th of 50
91 · median 56
Started
2009
the only one that year
Phase 2
25 of 50
5 open now
Registered
26th of 50
by date
Lead sponsor
10 of 50
Novartis Pharmaceuticals

Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 17th largest by enrollment, is the only one that started in 2009, is one of 25 in phase 2, and was the 26th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing imatinib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST.

Read the detailed description

This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The primary endpoint is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST. A total of 85 adult patients, 18 years of age and older will be enrolled.Participants will take 400 mg of imatinib mesylate daily by mouth for a total of 5 years. At the conclusion of the treatment period, patients will be followed for 2 years for survival, status of response and antineoplastic treatments and quality of life.

03

Conditions studied

  • Gastrointestinal Stromal Tumor (GIST)

Keywords

  • Imatinib
  • Protein Kinase Inhibitors
  • Gastrointestinal Stromal Tumors
  • Digestive System Diseases
  • Digestive System Neoplasms
  • Gastrointestinal Diseases
  • Gastrointestinal Neoplasms
  • Adjuvant
  • PERSIST
  • PERSIS-5
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years of age or older.
  2. Patient must have had a histological diagnosis of primary GIST.
  3. The tumor must expressed KIT (CD117) protein by immunohistochemistry performed by central pathology.
  4. Patient must have been at significant risk of tumor recurrence as defined by either:

    • Primary GIST (any site): ≥ 2 cm and a mitotic rate of ≥ 5/50 HPF's
    • Non-gastric primary GIST: ≥ 5cm
  5. Patient must have undergone complete gross resection of a primary GIST within 12 weeks prior to first dose of imatinib study drug. The inclusion of R1 resections will be reviewed on a case by case basis by the Study Management Committee.
  6. Patient must had no evidence of GIST on either 1) a post-operative CT of the abdomen and pelvis with intravenous and oral contrast or 2) MRI of the abdomen and pelvis with intravenous contrast. CT or MRI must have been performed within 8 weeks prior to first dose of imatinib study drug.
  7. Performance status 0 or 1 ()
  8. Patient must had the following post-operative laboratory values confirmed within 14 days prior to first dose of imatinib study drug:

    • total \< 1.5 x NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study.
    • and AST \< 2.5 x ULN
    • creatinine \< 1.5 x ULN
    • > 1.5 x 109/L
    • > 100 x 109/L
  9. If patient is a cancer survivor, ALL of the following criteria apply:

    • Patient had undergone potentially curative therapy for all prior .
    • No evidence of any prior malignancies for at least 3 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone).
    • Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.
  10. Female patients of must have had negative pregnancy test within 7 days before initiation of study drug dosing. women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of must have jagreed to employ an effective barrier method of throughout the study and for up to 7 days following discontinuation of study drug.
  11. Written, voluntary .

Exclusion criteria

Exclusion Criteria:

  1. Patient has GIST to the peritoneum, liver, lymph node, or other sites or recurrent GIST.
  2. Prior treatment for GIST with the exception of prior treatment with imatinib adjuvant lasting ≤ 8 weeks following gross surgical resection.
  3. Patient has received any other agents within 28 days of first day of study drug dosing.
  4. Patient with Grade III/IV cardiac problems as defined by the Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
  5. Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risk or compromise compliance with the protocol (i.e., uncontrolled diabetes, chronic renal disease, chronic liver disease, or active uncontrolled infection).
  6. Patient has a known diagnosis of (HIV) infection.
  7. Patient receiving concurrent treatment with warfarin (acceptable alternative: low-molecular weight heparin).
  8. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable .

    -

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Imatinib

    All subjects received in tablet form imatinib (STI571) 400 mg once daily.

    Drug: imatinib mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Recurrence-free Survival up to 60 Months

    Recurrence-free survival assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event).

    Time frame: Baseline up to 60 months

  2. Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months

    Recurrence-free survival (RFS) assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). RFS estimates were summarized using the Kaplan-Meier product-limit method (Kaplan 1958). Censoring rules for RFS with the earliest occurring rule used in the analysis: subjects without objective recurrence of disease who were alive at the time of their discontinuation from study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment and subjects recording antineoplastic therapy during the study were censored on the date of the therapy initiated

    Time frame: Baseline up to 60 months

Secondary outcomes

  1. Overall Survival (OS) at 60 Months

    Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.

    Time frame: Baseline up to approximately 60 months

  2. Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months

    Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.

    Time frame: Baseline up to appoximately 60 months

07

Results

Posted Mar 14, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneImatinib
Started91
Safety set91
Full analysis set (fas)91
Completed46
Not completed45
Withdrew: Adverse event15
Withdrew: Death2
Withdrew: Withdrawal by subject19
Withdrew: Lost to follow-up3
Withdrew: Administrative problems1
Withdrew: Disease progression/relapse1
Withdrew: Protocol violation4
Post Treatment After Survival Follow-up
Participant flow — Post Treatment After Survival Follow-up
MilestoneImatinib
Started68
Completed57
Not completed11
Withdrew: Death1
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up5
Withdrew: Administrative problems4

Outcome measures

PrimaryRecurrence-free Survival up to 60 Months

Recurrence-free survival assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event).

Time frame:
Baseline up to 60 months
Reported as:
Number · participants with an event
Recurrence-free Survival up to 60 Months
participants with an eventImatinib
Subject with an event9
Event = disease recurrence7
Event=death2
Subjects censored82
PrimaryKaplan-Meier Estimates for Recurrence-free Survival up to 60 Months

Recurrence-free survival (RFS) assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). RFS estimates were summarized using the Kaplan-Meier product-limit method (Kaplan 1958). Censoring rules for RFS with the earliest occurring rule used in the analysis: subjects without objective recurrence of disease who were alive at the time of their discontinuation from study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment and subjects recording antineoplastic therapy during the study were censored on the date of the therapy initiated

Time frame:
Baseline up to 60 months
Reported as:
Number · percentage of patients
Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months
percentage of patientsImatinib
12 months97.7 (91.1 to 99.4)
18 months97.7 (91.1 to 99.4)
24 months96.5 (89.6 to 98.9)
36 months95.1 (87.5 to 98.2)
48 months95.1 (87.5 to 98.2)
60 months90.1 (80.0 to 95.2)
SecondaryOverall Survival (OS) at 60 Months

Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.

Time frame:
Baseline up to approximately 60 months
Reported as:
Number · participants
Overall Survival (OS) at 60 Months
participantsImatinib
subjects who died3
subjects censored88
SecondaryKaplan-Meier Estimates for Overall Survival (OS) up to 60 Months

Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.

Time frame:
Baseline up to appoximately 60 months
Reported as:
Number · percentage of participants
Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months
percentage of participantsImatinib
12 months100.00 (100.00 to 100.00)
18 months100.00 (100.00 to 100.00)
24 months98.0 (86.4 to 99.7)
36 months98.0 (86.4 to 99.7)
48 months98.0 (86.4 to 99.7)
60 months93.8 (82.0 to 98.0)

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib—28/91 (30.8%)91/91 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventImatinib
ANAEMIABlood and lymphatic system disorders4/91
PNEUMONIAInfections and infestations4/91
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders3/91
PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/91
ABDOMINAL PAINGastrointestinal disorders2/91
NAUSEAGastrointestinal disorders2/91
VOMITINGGastrointestinal disorders2/91
MALAISEGeneral disorders2/91
PERITONITISInfections and infestations2/91
HIP FRACTUREInjury, poisoning and procedural complications2/91
Most frequent other events
Showing 10 of 64
Most frequent other events
EventImatinib
NAUSEAGastrointestinal disorders65/91
DIARRHOEAGastrointestinal disorders57/91
FATIGUEGeneral disorders45/91
MUSCLE SPASMSMusculoskeletal and connective tissue disorders37/91
VOMITINGGastrointestinal disorders34/91
PERIORBITAL OEDEMAEye disorders31/91
RASHSkin and subcutaneous tissue disorders24/91
ABDOMINAL PAINGastrointestinal disorders22/91
HEADACHENervous system disorders20/91
OEDEMA PERIPHERALGeneral disorders18/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)Imatinib
Mean58.9 ± 12.64
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib
Female43
Male48
ECOG Status
ECOG Status(Participants)Imatinib
ECOG = 059
ECOG = 132
Primary lesion location
Primary lesion location(participant)Imatinib
Gastric50
Duodenum4
Jejunum ileum21
Rectum1
Other15
Abdomen1
Abdominal; Proximal Jejunal1
Exact Location In Small Bowel Not Identified1
Gastric Serosa-Min Invasion Outer Musc Prop1
Ileum And Cecum1
Pelvis - Organ Of Origin Unknown1
Recto Vaginal1
Retroperitoneal Mass1
Sigmoid Colon1
Small Bowel6
08

Study locations

21 sites
  • University of California San Diego - Moores Cancer Center Moores UCSD Cancer Center (31)
    La Jolla, California 92093-0658, United States
  • University of Colorado University of Colorado
    Aurora, Colorado 80045, United States
  • Washington Hospital Center Department of Medical Oncology
    Washington, District of Columbia 20010, United States
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
  • Longstreet Cancer Center
    Gainesville, Georgia 30501, United States
  • Kootenai Medical Center Kootenai Cancer Cancer
    Coeur d'Alene, Idaho 83814, United States
  • North Shore University Health System
    Evanston, Illinois 60201, United States
  • Dana Farber Cancer Institute Dana-Farber
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute Karmonos Cancer Instit. (40)
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine Center for Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Southern Nevada Cancer Research Foundation S. Nevada Cancer Res (2)
    Las Vegas, Nevada 89106, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (7)
    New York, New York 10021, United States
  • Duke University Medical Center Duke University Med Ctr (8)
    Durham, North Carolina 27710, United States
  • Oregon Health & Science University OHS University
    Portland, Oregon 97239, United States
  • Penn State University / Milton S. Hershey Medical Center Penn Stat University
    Hershey, Pennsylvania 17033-0850, United States
  • Roger Williams Medical Center Medical Center
    Providence, Rhode Island 02908, United States
  • Kingport Hematology Oncology
    Kingsport, Tennessee 37660, United States
  • MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (4)
    Houston, Texas 77030, United States
  • South Texas Oncology and Hematology, PA South Texas Onc/Hem
    San Antonio, Texas 78259, United States
  • Virginia Oncology Associates Viriginia Oncology Assoc.
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):e184060. doi: 10.1001/jamaoncol.2018.4060. Epub 2018 Dec 13. PubMed 30383140 ↗
  • Essat M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer. 2011 May 1;128(9):2202-14. doi: 10.1002/ijc.25827. PubMed 21387287 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2009 to primary completion in Dec 2016, 88 months.

Results were first posted in Mar 2018, 1 year 2 months after primary completion.

Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's 88 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
StartActual
Jul 22, 2009
Primary completionActual
Dec 20, 2016
CompletionActual
Dec 20, 2016
Results first posted
Mar 14, 2018
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00867113
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
Jul 22, 2009
Primary completion
Dec 20, 2016
Completion
Dec 20, 2016
Results posted
Mar 14, 2018
Last update
Mar 14, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion